Related Experiment Videos
The role of hyperglycemia in FAT/CD36 expression and function
Min Chen1, Ying-Kui Yang, Tara J Loux
1Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Pediatric Surgery International
|July 14, 2006
Summary
High blood glucose, not insulin, significantly increases FAT/CD36 expression in type 1 diabetes. This finding highlights glucose control as crucial for managing FAT/CD36 levels in diabetes.
Area of Science:
- Metabolic diseases
- Molecular biology
- Endocrinology
Background:
- FAT/CD36 is a fatty acid transporter and scavenger receptor implicated in hypertriglyceridemia and insulin resistance.
- FAT/CD36 expression is elevated in type 1 diabetes, but the roles of glucose and insulin in this regulation are unclear.
Purpose of the Study:
- To investigate the independent effects of plasma glucose and insulin on FAT/CD36 mRNA expression in a rat model of type 1 diabetes.
Main Methods:
- Type 1 diabetes was induced in rats using streptozotocin (STZ).
- Rats were treated with either insulin or vanadate (a glucose-lowering agent independent of insulin signaling).
- FAT/CD36 mRNA levels were measured in various tissues.
Main Results:
- STZ-induced diabetes increased FAT/CD36 mRNA in the intestine, adipose tissue, and heart.
- Insulin treatment normalized body weight, blood glucose, and FAT/CD36 mRNA levels.
- Vanadate treatment reduced blood glucose and normalized FAT/CD36 mRNA levels without affecting body weight or insulin levels.
Conclusions:
- Plasma glucose levels play a more significant role in regulating FAT/CD36 expression than insulin levels in type 1 diabetes.
- These findings suggest that controlling hyperglycemia is critical for modulating FAT/CD36 expression.